McCleland et al. [54] developed a CRISPR loss-of-function screen and conducted a high-throughput screen to recognize an epigenetic modulators including bromodomain-containing protein 4 (BRD4), which revealed that BRD4 is involving in colon cancer cell proliferation, and its knockdown resulted in differentiation and growth arrest in the epigenetically dysregulated CpG island methylator phenotype (CIMP+) class of cancers. The gene discussed is BRD4; the disease is malignant colon neoplasm.